Literature DB >> 7539024

Increased nitric oxide production in endotoxin-induced uveitis. Reduction of uveitis by an inhibitor of nitric oxide synthase.

O Goureau1, J Bellot, B Thillaye, Y Courtois, Y de Kozak.   

Abstract

Nitric oxide (NO) has been implicated in the pathogenesis of several inflammatory diseases. In the present study, we investigated the potential role of NO in an ocular model of inflammation, endotoxin-induced uveitis (EIU), in Lewis rats. Injection of LPS in one footpad induces severe uveitis after 16 h, which is accompanied by an increase of NO in the aqueous and vitreous humors, as evaluated by nitrite assay. Reverse transcriptase-PCR experiments reveal a large increase of inducible NO synthase (iNOS) mRNA in the iris/ciliary body, from 2 to 24 h after LPS treatment. In the retina, maximal increase of iNOS mRNA was detected 16 h after LPS treatment. Two i.p. injections of the NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), which inhibits nitrite release in the aqueous and vitreous humors, profoundly reduce clinical and histologic inflammation in EIU rats. These results implicate the NO pathway in the pathogenesis of EIU and demonstrate the possibility of modulating this inflammatory disease by injection of a NOS inhibitor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Anterior uveitis: clinical and research perspectives.

Authors:  J T Rosenbaum; T M Martin; S R Planck
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Apoptosis is a prominent feature of acute anterior uveitis in the Fischer 344 rat.

Authors:  J R Smith; P H Hart; S D Standfield; D J Coster; S J Wing; K A Williams
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

3.  Suppressive effects of selectin inhibitor SKK-60060 on the leucocyte infiltration during endotoxin induced uveitis.

Authors:  K Yamashiro; J Kiryu; A Tsujikawa; A Nonaka; K Nishijima; H Kamizuru; K Miyamoto; Y Honda; T Jomori; Y Ogura
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

4.  The protective role of topical propolis on experimental keratitis via nitric oxide levels in rabbits.

Authors:  N Duran; A Koc; H Oksuz; C Tamer; Y Akaydin; T Kozlu; M Celik
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

5.  Anti-inflammatory effects of specific cyclooxygenase 2,5-lipoxygenase, and inducible nitric oxide synthase inhibitors on experimental autoimmune anterior uveitis (EAAU).

Authors:  Nalini S Bora; Jeong-Hyeon Sohn; Puran S Bora; Henry J Kaplan; Prasad Kulkarni
Journal:  Ocul Immunol Inflamm       Date:  2005 Apr-Jun       Impact factor: 3.070

6.  Case of lens-induced uveitis associated with supernormal flicker ERG amplitudes after cataract surgery.

Authors:  Kumiko Kato; Asako Sugawara; Ryunosuke Nagashima; Masahiko Sugimoto; Kengo Ikesugi; Hisashi Matsubara; Maki Takeuchi; Mineo Kondo
Journal:  Doc Ophthalmol       Date:  2020-08-17       Impact factor: 2.379

7.  Additive effect of nitric oxide and prostaglandin-E2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit.

Authors:  J L Bellot; M Palmero; C García-Cabanes; R Espí; C Hariton; A Orts
Journal:  Inflamm Res       Date:  1996-04       Impact factor: 4.575

8.  Folic Acid, Vitamin B6, and Vitamin B12 in Combination and Age-Related Cataract in a Randomized Trial of Women.

Authors:  William G Christen; Robert J Glynn; Emily Y Chew; Christine M Albert; JoAnn E Manson
Journal:  Ophthalmic Epidemiol       Date:  2016-01-20       Impact factor: 1.648

9.  Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy.

Authors:  F Sennlaub; Y Courtois; O Goureau
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

10.  Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation.

Authors:  Li-ping Yang; Xiu-an Zhu; Mark O M Tso
Journal:  Mol Vis       Date:  2007-07-09       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.